Do you want to read an article? Please log in or register.
Pharmacokinetics and safety of clofazimine in children with rifampicin-resistant tuberculosis
Tuberculosis
Related content
Tuberculosis
Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin-resistant tuberculosis
Br J Clin Pharmacol
Palmer M, Zou Y, Hesseling AC, van der Laan L, Courtney I, Kinikar AA, Sonkawade N, Paradkar M, Kulkarni V, Casalme DJO, Frias MVG, Draper H, Wiesner L, Karlsson MO, Denti P, Svensson EM, Garcia-Prats AJ
doi: 10.1002/bcp.70005
Tuberculosis
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial
Lancet Respir Med
Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Ali MH, Amjad S, Kamal F, Abubakirov A, Ardizzoni E, Baudin E, Bektassov S, Berry C, Bonnet M, Chavan V, Coutisson S, Dakenova Z, de Jong BC, Dinh LV, Ferlazzo G, Kirakosyan O, Lachenal N, Lecca L, McIlleron H, Mikanda KK, Mucching-Toscano S, Mulders W, Mushtaque H, Nahid P, Nguyen DV, Nguyen NV, Oyewusi L, Motta I, Panda S, Patil S, Pham TH, Phan DT, Phan HTT, Phillips PPJ, Ruiz J, Rupasinghe P, Salahuddin N, Sanchez-Garavito E, Seung KJ, Asfaw MT, Vargas Vasquez D, Rich ML, Varaine F, Mitnick CD, endTB-Q Clinical Trial Team
doi: 10.1016/S2213-2600(25)00194-8
RECOMMENDED
Tuberculosis
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Goodall RL, Nunn AJ, Meredith SK, Bayissa A, Bhatnagar AK, Chiang CY, Conradie F, Gopalan N, Gurumurthy M, Kirenga B, Kiria N, Meressa D, Moodliar R, Ngubane N, Rassool M, Sanders K, Solanki R, Squire SB, Teferi M, Torrea G, Tsogt B, Tudor E, Van Deun A, Rusen ID, STREAM study collaborators
doi: 10.1016/S2213-2600(24)00186-3
RECOMMENDED
Tuberculosis
Safety, Efficacy and Pharmacokinetics of daily optimised doses of Rifampicin for the Treatment of Tuberculosis: A Systematic Review and Bayesian Network Meta-Analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Infect Dis
Espinosa-Pereiro J, Aguiar A, Nara E, Medina A, Molinas G, Tavares M, Tortola T, Ghimire S, Alfenaar JC, Sturkenboom MGG, Magis-Escurra C, Sánchez-Montalva A, Barros H, Duarte R
doi: 10.1093/cid/ciaf003
RECOMMENDED
Tuberculosis
Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Am J Respir Crit Care Med
Saukkonen JJ, Duarte R, Munsiff SS, Winston CA, Mammen MJ, Abubakar I, Acuña-Villaorduña C, Barry PM, Bastos ML, Carr W, Chami H, Chen LL, Chorba T, Daley CL, Garcia-Prats AJ, Holland K, Konstantinidis I, Lipman M, Battista Migliori G, Parvez FM, Shapiro AE, Sotgiu G, Starke JR, Starks AM, Thakore S, Wang SH, Wortham JM, Nahid P
doi: 10.1164/rccm.202410-2096ST
RECOMMENDED
Pneumonia
Impact of Multidrug-Resistant Bacteria in a Cohort of COVID-19 Critically Ill Patients: Data from a Prospective Observational Study Conducted in a High-Antimicrobial-Resistance-Prevalence Center
★ 2
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med
Montrucchio G, Grillo F, Balzani E, Gavanna G, Sales G, Bonetto C, Simonetti U, Zanierato M, Fanelli V, Filippini C, Corcione S, De Rosa FG, Curtoni A, Costa C, Brazzi L
doi: 10.3390/jcm14020410
RECOMMENDED
Tuberculosis
Telacebec, A Potent Agent in the Fight Against Tuberculosis: Findings from A Randomized, Phase 2 Clinical Trial and Beyond
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Am J Respir Crit Care Med
Janssen S, Upton C, de Jager VR, van Niekerk C, Dawson R, Hutchings J, Kim J, Choi J, Nam K, Sun E, Diacon AH
doi: 10.1164/rccm.202408-1632OC
Tuberculosis
Effects of conditional cash transfers and pre-test and post-test tuberculosis counselling on patient outcomes and loss to follow-up across the continuum of care in South Africa: a randomised controlled trial
Lancet Infect Dis
Ismail N, Moultrie H, Mwansa-Kambafwile J, Copas A, Izu A, Moyo S, Skinner D, Ismail F, Gosce L, Omar SV, Abubakar I, Madhi SA
doi: 10.1016/S1473-3099(24)00816-8
RECOMMENDED
Pulmonary Fibrosis
Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Hoppe JE, Kasi AS, Pittman JE, Jensen R, Thia LP, Robinson P, Tirakitsoontorn P, Ramsey B, Mall MA, Taylor-Cousar JL, McKone EF, Tullis E, Salinas DB, Zhu J, Chen YC, Rodriguez-Romero V, Sosnay PR, Davies G
doi: 10.1016/S2213-2600(24)00407-7